Cohance Lifesciences Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Equivalents	-	491.4	966.5	472.3	648.03	445.64
Short-Term Investments	-	46.6	94.7	-	-	-
Trading Asset Securities	-	2,663	1,917	7,739	4,189	4,812
Cash & Short-Term Investments	3,260	3,201	2,979	8,211	4,837	5,258
Cash Growth	16.25%	7.47%	-63.73%	69.75%	-8.00%	180.01%
Accounts Receivable	-	7,014	7,883	1,337	1,109	2,364
Other Receivables	-	1,631	1,585	562.3	665.92	480.04
Receivables	-	8,724	9,493	1,907	1,777	2,846
Inventory	-	5,622	4,674	2,332	3,306	3,000
Prepaid Expenses	-	248.9	207.9	49.2	86.28	64
Other Current Assets	-	482.8	582	32.7	103.79	111.67
Total Current Assets	-	18,280	17,935	12,532	10,110	11,279
Property, Plant & Equipment	-	21,633	20,964	7,868	7,662	5,620
Long-Term Investments	-	2,645	1,458	1,306	1,171	1,171
Goodwill	-	12,837	12,390	602.5	602.58	-
Other Intangible Assets	-	995.2	1,064	16.8	19.32	22.36
Long-Term Deferred Tax Assets	-	26.4	5.5	8.1	-	-
Other Long-Term Assets	-	867.7	885.4	216	91.64	203.02
Total Assets	-	57,296	54,810	22,549	19,657	18,296

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Accounts Payable	-	2,846	2,684	423.5	700.92	1,059
Accrued Expenses	-	938.9	1,021	256.9	128.17	266
Short-Term Debt	-	744.3	706.5	385.8	445.98	471.33
Current Portion of Long-Term Debt	-	447.6	579.6	-	200	200
Current Portion of Leases	-	252.5	364.5	51.9	4.79	10.91
Current Income Taxes Payable	-	164.4	75.2	-	2.94	36.42
Current Unearned Revenue	-	247.1	43	6.9	8.08	-
Other Current Liabilities	-	818.7	1,580	49	96.79	59.27
Total Current Liabilities	-	6,459	7,054	1,174	1,588	2,103
Long-Term Debt	-	504.8	1,298	-	45.64	284.4
Long-Term Leases	-	2,056	1,911	212.4	7	4.63
Pension & Post-Retirement Benefits	-	4	2.6	-	-	11.09
Long-Term Deferred Tax Liabilities	-	979	1,026	656	582.35	543.15
Other Long-Term Liabilities	-	6,955	5,590	-	82.95	77.85
Total Liabilities	-	16,958	16,881	2,042	2,306	3,024

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Common Stock	-	382.6	254.6	254.6	254.57	254.57
Additional Paid-In Capital	-	2,722	2,694	1,096	1,096	1,096
Retained Earnings	-	24,001	22,150	18,894	15,894	13,820
Comprehensive Income & Other	-	12,007	11,389	262.3	107.17	101.65
Total Common Equity	39,113	39,113	36,488	20,507	17,352	15,272
Minority Interest	-	1,225	1,441	-	-	-
Shareholders' Equity	40,338	40,338	37,929	20,507	17,352	15,272
Total Liabilities & Equity	-	57,296	54,810	22,549	19,657	18,296

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Total Debt	4,005	4,005	4,859	650.1	703.41	971.27
Net Cash (Debt)	-745.1	-803.7	-1,881	7,561	4,134	4,287
Net Cash Growth	-	-	-	82.90%	-3.56%	858.10%
Net Cash Per Share	-	-2.10	-4.90	29.70	16.24	16.84
Filing Date Shares Outstanding	-	382.57	382.57	254.56	254.56	254.56
Total Common Shares Outstanding	-	382.57	254.56	254.56	254.56	254.56
Working Capital	-	11,820	10,881	11,358	8,523	9,176
Book Value Per Share	102.03	102.24	143.34	80.56	68.16	59.99
Tangible Book Value	25,281	25,281	23,035	19,887	16,730	15,249
Tangible Book Value Per Share	65.95	66.08	90.49	78.12	65.72	59.90
Land	-	797.8	827.2	150.5	150.46	150.46
Buildings	-	6,278	5,197	2,206	2,200	1,813
Machinery	-	17,234	14,697	5,797	5,410	4,750
Construction In Progress	-	1,732	3,316	1,790	1,651	299.94
Leasehold Improvements	-	267.8	252.3	42.6	-	-